Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

NCT01929200 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: 1-year treatment with icotinib
DRUG: 2-year treatment with icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.